Evidence has indicated that PD-L1 is generally upregulated in NSCLC patients, with PD-1 expressed on most tumor infiltrating lymphocytes (TILs), supporting the rationale for the development of monoclonal antibodies against PD-L1 or PD-1, which are currently under investigation. This evidence concerns the gene CD274 and neoplasm.